SillaJen, a Seoul, Korea-headquartered clinical-stage, biotherapeutics company developing oncolytic immunotherapy products for cancer, has expanded its manufacturing pact with ABL Europe, a contract development and manufacturing organization (CDMO) for viral vector GMP services for gene therapy, oncolytic products, and vaccines.

Under the current agreement, ABL is manufacturing Pexa-Vec, SillaJen’s investigational liver cancer drug, for SillaJen’s Phase III clinical trial of Pexa-Vec. Under the expanded agreement, ABL will also provide development, manufacturing, and quality control release testing services for SillaJen’s pipeline product, JX-970, another oncolytic virus immunotherapy.

Source: ABL Europe